1-cbz-4-乙烯基-4-羟基哌啶 | 946429-50-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-cbz-4-乙烯基-4-羟基哌啶
• 英文名称: 1-carboxybenzyl-4-vinylpiperidin-4-ol
• 英文别名: 4-hydroxy-4-vinyl-piperidine-1-carboxylic acid benzylester；phenylmethyl 4-ethenyl-4-hydroxy-1-piperidinecarboxylate；4-Hydroxy-4-vinyl-piperidine-1-carboxylic acid benzyl ester；benzyl 4-ethenyl-4-hydroxypiperidine-1-carboxylate
• CAS: 946429-50-1
• 化学式: C₁₅H₁₉NO₃
• 分子量: 261.321
• InChiKey: ITTXZJWADRUXBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-cbz-4-乙烯基-4-羟基哌啶 在 硫酸 作用下， 以 乙醚 为溶剂， 反应 1.0h， 生成 benzyl 4-vinyl-3,6-dihydropyridine-1(2H)-carboxylate
  参考文献：
  名称：

  Synthesis and antibacterial activity of new 7-(aminoazabicycloalkanyl)quinolonecarboxylic acids

  摘要：

  A series of novel 7-[amino-substituted azabicycloalkanyl]-6-fluoro-1-substituted quinolinecarboxylic acids (18-53) have been prepared and their antibacterial activities evaluated. These compounds are characterized structurally by a new amino-substituted azabicyclo[3.3.0]octane,-[4.3.0]nonane and -[5.3.0]decane ring systems at the 7-position of quinolonecarboxylic acids. To compare the biological activities of enantiomers, (+)-7[(1S, 5R)- and (-)-7[(1R, 5S)-1-aminomethyl-3-azabicyclo[3.3.0]-octan-3-yl]-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolonecarboxylic acid hydrochloride (43, 44) were synthesized and evaluated for antibacterial activity. Compound 43 was more potent than 44 against both Gram-positive and Gram-negative organisms. The structure-activity relationships of these quinolonecarboxylic acids are also discussed.

  DOI：

  10.1016/0223-5234(91)90131-6
• 作为产物：
  描述：

  1-Cbz-4-哌啶酮 、 乙烯基溴化镁 在 cerium(III) chloride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 1-cbz-4-乙烯基-4-羟基哌啶
  参考文献：
  名称：

  铁催化下 C-OH 裂解和硼转移相结合的烯丙醇立体选择性脱羟基硼酸制备 (E)-烯丙基硼酸酯

  摘要：

  铁催化的烯丙醇直接 S N 2' 脱羟基硼酸已被开发用于获得 ( E )-立体选择性烯丙基硼酸酯。具有多种结构和官能团的烯丙醇，特别是来自天然产物的烯丙醇，经历了平稳的转变。由烯丙醇和铁-硼中间体形成的六元环过渡态被证明是参与硼基团转移、C-OH键活化和立体选择性控制的关键成分。

  DOI：

  10.1021/acs.orglett.1c03359

文献信息

• [EN] HEPATITIS B ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX DE L'HÉPATITE B
  申请人：ENANTA PHARM INC

  公开号：WO2020247575A1

  公开（公告）日：2020-12-10

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了化合物的结构式(I)，或其药学上可接受的盐：这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可作为抗病毒药剂使用。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给予含有本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS
  申请人：Eidam Hilary Schenck

  公开号：US20080318990A1

  公开（公告）日：2008-12-25

  The present invention relates to a compound of the following formula: where R 1 -R 6 , R 10 , Y, n, m, p, and q are as defined herein. Compounds and compositions of the present invention are useful for the treatment of diseases associated with the overexpression of CCR2.

  本发明涉及以下式的化合物：其中R1-R6、R10、Y、n、m、p和q如本文所定义。本发明的化合物和组合物对于治疗与CCR2过度表达相关的疾病是有用的。
• SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS
  申请人：DeMong E. Duane

  公开号：US20070197590A1

  公开（公告）日：2007-08-23

  Substituted dipiperidine compounds of Formula (I) or a form thereof, which are CCR2 antagonists and are useful in preventing, treating or ameliorating CCR2 mediated inflammatory syndromes, disorders or diseases in a subject in need thereof.

  Formula (I)中的取代二哌啶化合物或其形式，它们是CCR2拮抗剂，可用于预防、治疗或改善需要的主体中的CCR2介导的炎症综合征、紊乱或疾病。
• Ring-closing metathesis strategy to unsaturated γ- and δ-lactones: Synthesis of hydroxyethylene isostere for protease inhibitors
  作者：Arun K. Ghosh、John Cappiello、Dongwoo Shin

  DOI：10.1016/s0040-4039(98)00887-9

  日期：1998.6

  acrylates derived from allylic and homo allylic alcohols in the presence of the Grubbs' catalyst (10–15 mol%) and titanium isopropoxide (0.3–3 equiv) provided ready access to α, β-unsaturated γ- and δ-lactones and an important dipeptide isostere intermediate.

  在Grubbs催化剂（10-15摩尔％）和异丙氧基钛（0.3-3当量）存在下，由烯丙基和均烯丙基醇衍生的丙烯酸酯的闭环烯烃复分解提供了现成的α，β-不饱和γ-和δ-内酯和重要的二肽等排中间体。
• [EN] OXAZOLES AS MODULATORS OF CHEMOKINE RECEPTORS<br/>[FR] OXAZOLES EN TANT QUE MODULATEURS DES RÉCEPTEURS DE LA CHIMIOKINE
  申请人：GLAXO GROUP LTD

  公开号：WO2010080873A1

  公开（公告）日：2010-07-15

  The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein R1-R7, X, Y, m, and n are as described herein. Compounds of the present invention are useful for the treatment of a variety of diseases associated with overexpression of the CCR2 receptor.

  本发明涉及一种化合物，其化学式为（I）：或其药用可接受的盐；其中R1-R7、X、Y、m和n如本文所述。本发明的化合物对治疗与CCR2受体过度表达相关的各种疾病有用。